Published by
Ministry of Health, Labour and Welfare

Translated by
Pharmaceuticals and Medical Devices Agency

Revision of Precautions

Pomalidomide

January 26, 2021

Therapeutic category

Other antitumor agents

Non-proprietary name

Pomalidomide

Safety measure

Precautions should be revised in the package insert.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

Revision in line with the Instructions for Package Inserts of Prescription Drugs, PAB Notification No. 606 by the Director General of Pharmaceutical Affairs Bureau, MHW, dated April 25, 1997 (Old instructions): Revised language is underlined.

Current	Revision
Adverse Reactions Clinically Significant adverse Reactions (N/A)	Adverse Reactions Clinically Significant adverse Reactions Progressive multifocal leukoencephalopathy (PML): Progressive multifocal leukoencephalopathy (PML) may occur. Patients should be carefully monitored during, and after, the treatment with this drug, and if symptoms such as disturbed consciousness, cognitive disorder, paralytic symptoms (hemiplegia or quadriplegia), dyslalia, or speech loss are observed, diagnostic imaging through MRI and cerebrospinal fluid test should be performed, administration should be discontinued, and appropriate measures should be taken.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

Revision in line with the Instructions for Package Inserts of Prescription Drugs, etc. PSEHB Notification No. 0608-1 by the Director of Pharmaceutical Safety and Environmental Health Bureau, MHLW, dated June 8, 2017 (New instructions): Revised language is underlined.

Current	Revision
11. ADVERSE REACTIONS 11.1 Clinically Significant adverse Reactions (N/A)	11. ADVERSE REACTIONS 11.1 Clinically Significant adverse Reactions Progressive multifocal leukoencephalopathy (PML) Patients should be carefully monitored during, and after, the treatment with this drug, and if symptoms such as disturbed consciousness, cognitive disorder, paralytic symptoms (hemiplegia or quadriplegia), dyslalia, or speech loss are observed, diagnostic imaging through MRI and cerebrospinal fluid test should be performed, administration should be discontinued, and appropriate measures should be taken.

(N/A): Not Applicable, because the section is not included in the current package insert.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp